Investigating the neuroprotective role of Synta-66 in type-2 diabetes mellitus-induced dementia in rats
Journal of Pharmacy and Pharmacology · 04.09.2025 · 77 (9) · 1222-1243
DOI: 10.1093/jpp/rgaf036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 12.06.2025. Verfasst von Ashi Mannan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura , Punjab 140401, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Neuroprotective Agents, Diabetes Mellitus, Experimental, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Themen: Diabetes mellitus, Demenz
Abstract (Originalsprache)
Objectives
This study explores the potential inhibitory effects of Synta-66 at doses of 1 and 5 mg/kg, with a particular emphasis on the role of ORAI-I in amyloidogenesis, a common mechanism that underlies type-2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD).
Methods
Induction of T2DM-induced AD by the high-fat diet (HFD)-Streptozotocin (STZ)-Aβ25–35 model. Assessment of behavioral parameters like polydipsia, polyphagia, Morris water maze, and passive avoidance test; biochemical estimation of glucose, insulin, oxidative stress (superoxide dismutase (SOD), glutathione (GSH), catalase (Cat), and thiobarbituric acid reactive substances (TBARS)), neuroinflammation (interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), and nuclear factor-kappa B (NF-κβ)), Aβ level, through ELISA technique, and calcium levels via atomic absorption spectrometer. Key findings Synta-66 (5 and 10 mg/kg) results in a reduction in food and water intake, as well as a reduction in memory impairment in the Morris water maze and passive avoidance test. Furthermore, it normalizes glucose, insulin, and antioxidant elements (SOD, GSH, and Cat) level, while decreasing TBARS levels. In addition, ELISA data demonstrated a reduction in neuroinflammation (downregulation of IL-1β, IL-6, TNF-α, and NF-κβ), Aβ accumulation, and calcium levels by Synta-66 (5 and 10 mg/kg).
Conclusion
Consequently, ORAI can play a crucial role in the mediation of amyloidogenesis induced by T2DM, thereby establishing a connection between T2DM and AD. Therefore, Synta-66 has the potential to treat and prevent the progression of T2DM to AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Rajpura , Punjab 140401, India.
ORCID-Profile: Thakur Gurjeet Singh
Zitieren
APA
Mannan, A., Mohan, M., Singh, S., Dhiman, S., & Singh, T. G. (2025). Investigating the neuroprotective role of Synta-66 in type-2 diabetes mellitus-induced dementia in rats. Journal of Pharmacy and Pharmacology, 77(9), 1222-1243. https://doi.org/10.1093/jpp/rgaf036
Vancouver
Mannan A, Mohan M, Singh S, Dhiman S, Singh TG. Investigating the neuroprotective role of Synta-66 in type-2 diabetes mellitus-induced dementia in rats. Journal of Pharmacy and Pharmacology. 2025;77(9):1222-1243. doi:10.1093/jpp/rgaf036
BibTeX
@article{Mannan2025,
author = {Mannan, Ashi and Mohan, Maneesh and Singh, Shareen and Dhiman, Sonia and Singh, Thakur Gurjeet},
title = {Investigating the neuroprotective role of Synta-66 in type-2 diabetes mellitus-induced dementia in rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
volume = {77},
number = {9},
pages = {1222--1243},
doi = {10.1093/jpp/rgaf036}
}
EUVIMED